Osmosis Investment Management UK Ltd Acquires Shares of 46,169 Cardinal Health, Inc. $CAH

Osmosis Investment Management UK Ltd acquired a new position in Cardinal Health, Inc. (NYSE:CAH) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 46,169 shares of the company’s stock, valued at approximately $10,968,000.

Other hedge funds also recently made changes to their positions in the company. LWM Advisors Inc. grew its holdings in Cardinal Health by 4.4% during the 2nd quarter. LWM Advisors Inc. now owns 1,028 shares of the company’s stock valued at $244,000 after buying an additional 43 shares in the last quarter. Kathmere Capital Management LLC grew its position in shares of Cardinal Health by 1.2% during the 1st quarter. Kathmere Capital Management LLC now owns 4,242 shares of the company’s stock valued at $896,000 after purchasing an additional 49 shares in the last quarter. Hillsdale Investment Management Inc. increased its holdings in shares of Cardinal Health by 0.9% in the fourth quarter. Hillsdale Investment Management Inc. now owns 5,760 shares of the company’s stock worth $1,184,000 after purchasing an additional 50 shares during the period. V Square Quantitative Management LLC increased its holdings in shares of Cardinal Health by 2.6% in the first quarter. V Square Quantitative Management LLC now owns 2,002 shares of the company’s stock worth $423,000 after purchasing an additional 50 shares during the period. Finally, Generali Asset Management SPA SGR raised its position in shares of Cardinal Health by 11.0% in the fourth quarter. Generali Asset Management SPA SGR now owns 513 shares of the company’s stock worth $105,000 after buying an additional 51 shares in the last quarter. 87.17% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Cardinal Health

In related news, CEO Jason M. Hollar sold 44,529 shares of Cardinal Health stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $236.18, for a total value of $10,516,859.22. Following the transaction, the chief executive officer owned 190,603 shares in the company, valued at $45,016,616.54. This trade represents a 18.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jessica L. Mayer sold 29,436 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $236.19, for a total transaction of $6,952,488.84. Following the completion of the sale, the insider directly owned 33,076 shares of the company’s stock, valued at $7,812,220.44. This represents a 47.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 210,271 shares of company stock worth $49,626,657. Corporate insiders own 0.12% of the company’s stock.

Cardinal Health Stock Down 0.0%

Shares of CAH stock opened at $229.48 on Monday. The business has a 50-day moving average price of $232.02 and a two-hundred day moving average price of $217.86. Cardinal Health, Inc. has a 12-month low of $145.87 and a 12-month high of $258.30. The firm has a market cap of $53.37 billion, a P/E ratio of 31.74, a price-to-earnings-growth ratio of 1.23 and a beta of 0.49.

Cardinal Health (NYSE:CAH) last announced its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.42 by $0.49. The firm had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The company’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, research analysts expect that Cardinal Health, Inc. will post 12.54 EPS for the current fiscal year.

Cardinal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be paid a dividend of $0.5158 per share. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. Cardinal Health’s dividend payout ratio (DPR) is 28.49%.

Cardinal Health News Summary

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. William Blair started coverage on Cardinal Health in a research note on Tuesday, April 28th. They set an “outperform” rating for the company. UBS Group upped their target price on Cardinal Health from $274.00 to $280.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Zacks Research downgraded Cardinal Health from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 12th. Wells Fargo & Company lifted their price target on Cardinal Health from $245.00 to $277.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, Citigroup boosted their price objective on Cardinal Health from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Cardinal Health has an average rating of “Moderate Buy” and a consensus price target of $266.56.

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.